Identification of a novel topoisomerase inhibitor effective in cells overexpressing drug efflux transporters

PLoS ONE

Volumn 4, Issue 10, 2009, Pages

  Fayad, Walid ^a   Fryknäs, Mårten ^b   Brnjic, Slavica ^a   Olofsson, Maria Hägg ^a   Larsson, Rolf ^b   Linder, Stig ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE; CYTOCHROME C; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; ETOPOSIDE; GLYCOPROTEIN P; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN; PROTEIN BAK; PROTEIN BAX; THASPINE; UNCLASSIFIED DRUG; ALKALOID; ANTINEOPLASTIC AGENT; PLANT EXTRACT; TASPINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL MEMBRANE PERMEABILITY; CELL STRAIN HCT116; COLON CARCINOMA; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; CROTON; CROTON LECHLERI; DRUG EFFICACY; DRUG IDENTIFICATION; DRUG SCREENING; GENE EXPRESSION PROFILING; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MITOCHONDRIAL MEMBRANE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHYTOCHEMISTRY; PROTEIN CLEAVAGE; TUMOR XENOGRAFT; ANIMAL; CANCER TRANSPLANTATION; CARCINOMA; COLON TUMOR; DRUG ANTAGONISM; METABOLISM; PROTEIN CONFORMATION; TRANSPORT AT THE CELLULAR LEVEL; TUMOR CELL LINE;

CROTON LECHLERI;

ALKALOIDS; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BIOLOGICAL TRANSPORT; CARCINOMA; CELL LINE, TUMOR; COLONIC NEOPLASMS; CROTON; DNA TOPOISOMERASES, TYPE I; DRUG EVALUATION, PRECLINICAL; HUMANS; MICE; NEOPLASM TRANSPLANTATION; PLANT EXTRACTS; PROTEIN CONFORMATION;

EID: 70350007200     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0007238     Document Type: Article

References (58)

1. Nygren P, Larsson R (2003) Overview of the clinical efficacy of investigational anticancer drugs. J Intern Med 253: 46-75.
2. Kola I, Landis J (2004) Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 3: 711-715.
3. Kaufmann SH, Earnshaw WC (2000) Induction of apoptosis by cancer chemotherapy. Exp Cell Res 256: 42-49.
4. Koehn FE, Carter GT (2005) The evolving role of natural products in drug discovery. Nat Rev Drug Discov 4: 206-220.
5. Srivastava V, Negi AS, Kumar JK, Gupta MM, Khanuja SP (2005) Plant-based anticancer molecules: a chemical and biological profile of some important leads. Bioorg Med Chem 13: 5892-5908.
6. Arcamone FM (1998) From the pigments of the actinomycetes to third generation antitumor anthracyclines. Biochimie 80: 201-206.
7. Uehara Y (2003) Natural product origins of Hsp90 inhibitors. Curr Cancer Drug Targets 3: 325-330.
8. da Rocha AB, Lopes RM, Schwartsmann G (2001) Natural products in anticancer therapy. Curr Opin Pharmacol 1: 364-369.
9. Haägg M, Biven K, Ueno T, Rydlander L, Bjoörklund P, et al. (2002) A novel high-through-put assay for screening of pro-apoptotic drugs. Invest New Drugs 20: 253-259.
10. Zhang YM, He LC, Wang HY (2007) [Inhibitory effect of taspine on mouse S180 sarcoma and its mechanism]. Zhongguo Zhong Yao Za Zhi 32: 953-956.
11. Kramer G, Erdal H, Mertens HJ, Nap M, Mauermann J, et al. (2004) Differentiation between cell death modes using measurements of different soluble forms of extracellular cytokeratin 18. Cancer Res 64: 1751-1756.
12. Cummings J, Ward TH, Greystoke A, Ranson M, Dive C (2008) Biomarker method validation in anticancer drug development. Br J Pharmacol 153: 646-656.
13. Olofsson MH, Cummings J, Fayad W, Brnjic SRH, et al. Specific demonstration of drug-induced tumour cell apoptosis in human xenografts models using a plasma biomarker. Cancer Biomarkers in press.
14. Lemasters JJ, Nieminen AL, Qian T, Trost LC, Elmore SP, et al. (1998) The mitochondrial permeability transition in cell death: a common mechanism in necrosis, apoptosis and autophagy. Biochim Biophys Acta 1366: 177-196.
15. Wei MC, Zong WX, Cheng EH, Lindsten T, Panoutsakopoulou V, et al. (2001) Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science 292: 727-730.
16. Labi V, Erlacher M, Kiessling S, Villunger A (2006) BH3-only proteins in cell death initiation, malignant disease and anticancer therapy. Cell Death Differ 13: 1325-1338.
17. Gavathiotis E, Suzuki M, Davis ML, Pitter K, Bird GH, et al. (2008) BAX activation is initiated at a novel interaction site. Nature 455: 1076-1081.
18. Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, et al. (2006) The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 313: 1929-1935.
19. Danks MK, Schmidt CA, Cirtain MC, Suttle DP, Beck WT (1988) Altered catalytic activity of and DNA cleavage by DNA topoisomerase II from human leukemic cells selected for resistance to VM-26. Biochemistry 27: 8861-8869.
20. Bugg BY, Danks MK, Beck WT, Suttle DP (1991) Expression of a mutant DNA topoisomerase II in CCRF-CEM human leukemic cells selected for resistance to teniposide. Proc Natl Acad Sci U S A 88: 7654-7658.
21. Jonsson E, Fridborg H, Csoka K, Dhar S, Sundstrom C, et al. (1997) Cytotoxic activity of topotecan in human tumour cell lines and primary cultures of human tumour cells from patients. Br J Cancer 76: 211-219.
22. Wickstroöm M, Danielsson K, Rickardson L, Gullbo J, Nygren P, et al. (2007) Pharmacological profiling of disulfiram using human tumor cell lines and human tumor cells from patients. Biochem Pharmacol 73: 25-33.
23. Sutherland RM, Durand RE (1976) Radiation response of multicell spheroids - an in vitro tumour model. Curr Top Radiat Res Q 11: 87-139.
24. Sutherland RM (1988) Cell and environment interactions in tumor microregions: the multicell spheroid model. Science 240: 177-184.
25. Lloyd DG, Golfis G, Knox AJ, Fayne D, Meegan MJ, et al. (2006) Oncology exploration: charting cancer medicinal chemistry space. Drug Discov Today 11: 149-159.
26. Pieters L, de Bruyne T, Claeys M, Vlietinck A, Calomme M, et al. (1993) Isolation of a dihydrobenzofura lignan from South American Dragon's Blood (Croton Spp.) as an inhibitor of cell proliferation. J of Natural Products 56: 899-906.
27. Perdue GP, Blomster RN, Blake DA, Farnsworth NR (1979) South American plants II: taspine isolation and anti-inflammatory activity. J Pharm Sci 68: 124-126.
28. Zhang YM, He LC (2007) [Study on thaspine in inducing apoptosis of A549 cell]. Zhong Yao Cai 30: 429-432.
29. Itokawa H, Ichihara Y, Mochizuki M, Enomori T, Morita H, et al. (1991) A cytotoxic substance from Sangre de Grado. Chem Pharm Bull (Tokyo) 39: 1041-1042.
30. Zhang Y, He L, Meng L, Luo W, Xu X (2008) Suppression of tumor-induced angiogenesis by taspine isolated from Radix et Rhizoma Leonticis and its mechanism of action in vitro. Cancer Lett.
31. Pommier Y (2006) Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer 6: 789-802.
32. Teicher BA (2008) Next generation topoisomerase I inhibitors: Rationale and biomarker strategies. Biochem Pharmacol 75: 1262-1271.
33. Nitiss JL (2009) Targeting DNA topoisomerase II in cancer chemotherapy. Nat Rev Cancer 9: 338-350.
34. Denny WA, Baguley BC (2003) Dual topoisomerase I/II inhibitors in cancer therapy. Curr Top Med Chem 3: 339-353.
35. Dittrich C, Dieras V, Kerbrat P, Punt C, Sorio R, et al. (2003) Phase II study of XR5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with advanced ovarian cancer. Invest New Drugs 21: 347-352.
36. Ling V (1997) Multidrug resistance: molecular mechanisms and clinical relevance. Cancer Chemother Pharmacol 40 Suppl: S3-8.
37. Kobayashi H, Man S, Graham CH, Kapitain SJ, Teicher BA, et al. (1993) Acquired multicellular-mediated resistance to alkylating agents in cancer. Proc Natl Acad Sci U S A 90: 3294-3298.
38. Durand RE (1981) Flow cytometry studies of intracellular adriamycin in multicell spheroids in vitro. Cancer Res 41: 3495-3498.
39. Erlichman C, Vidgen D (1984) Cytotoxicity of adriamycin in MGH-U1 cells grown as monolayer cultures, spheroids, and xenografts in immune-deprived mice. Cancer Res 44: 5369-5375.
40. Herrmann R, Fayad W, Schwarz S, Berndtsson M, Linder S (2008) Screening for compounds that induce apoptosis of cancer cells grown as multicellular spheroids. J Biomol Screen 13: 1-8.
41. Lindhagen E, Nygren P, Larsson R (2008) The fluorometric microculture cytotoxicity assay. Nat Protoc 3: 1364-1369.
42. Wickstrom M, Danielsson K, Rickardson L, Gullbo J, Nygren P, et al. (2007) Pharmacological profiling of disulfiram using human tumor cell lines and human tumor cells from patients. Biochem Pharmacol 73: 25-33.
43. Griffiths GJ, Dubrez L, Morgan CP, Jones NA, Whitehouse J, et al. (1999) Cell damage-induced conformational changes of the pro-apoptotic protein Bak in vivo precede the onset of apoptosis. J Cell Biol 144: 903-914.
44. Mandic A, Viktorsson K, Molin M, Akusjarvi G, Eguchi H, et al. (2001) Cisplatin induces the proapoptotic conformation of bak in a deltamekk1-dependent manner. Mol Cell Biol 21: 3684-3691.
45. Yagi M, Nishimura T, Suzuki H, Tanaka N (1981) Chartreusin, an antitumor glycoside antibiotic, induces DNA strand scission. Biochem Biophys Res Commun 98: 642-647.
46. Chance B, Williams GR, Hollunger G (1963) Inhibition of electron and energy transfer in mitochondria. I. Effects of Amytal, thiopental, rotenone, progesterone, and methylene glycol. J Biol Chem 238: 418-431.
47. Gupta RS (1983) Podophyllotoxin-resistant mutants of Chinese hamster ovary cells: cross-resistance studies with various microtubule inhibitors and podophyllotoxin analogues. Cancer Res 43: 505-512.
48. Yamashita Y, Kawada S, Fujii N, Nakano H (1990) Induction of mammalian DNA topoisomerase II dependent DNA cleavage by antitumor antibiotic streptonigrin. Cancer Res 50: 5841-5844.
49. Bodley A, Liu LF, Israel M, Seshadri R, Koseki Y, et al. (1989) DNA topoisomerase II-mediated interaction of doxorubicin and daunorubicin congeners with DNA. Cancer Res 49: 5969-5978.
50. Seibert SF, Eguereva E, Krick A, Kehraus S, Voloshina E, et al. (2006) Polyketides from the marine-derived fungus Ascochyta salicorniae and their potential to inhibit protein phosphatases. Org Biomol Chem 4: 2233-2240.
51. Levinson C (1967) Effect of valinomycin on net sodium and potassium transport in Ehrlich ascites tumour cells. Nature 216: 74-75.
52. Brockman RW, Shaddix SC, Williams M, Struck RF (1976) Studies with 2,5-piperazinedione, 3,6-bis(5-chloro-2-piperidyl)-,dihydrochloride. II. Effects on macromolecular synthesis in cell culture and evidence for alkylating activity. Cancer Treat Rep 60: 1317-1324.
53. York J, Wolpert-DeFilippes MK, Johns DG, Sethi VS (1981) Binding of maytansinoids to tubulin. Biochem Pharmacol 30: 3239-3243.
54. Baldo P, Cecco S, Giacomin E, Lazzarini R, Ros B, et al. (2008) mTOR pathway and mTOR inhibitors as agents for cancer therapy. Curr Cancer Drug Targets 8: 647-665.
55. Radhakrishnan SK, Bhat UG, Hughes DE, Wang IC, Costa RH, et al. (2006) Identification of a chemical inhibitor of the oncogenic transcription factor forkhead box M1. Cancer Res 66: 9731-9735.
56. Vandenberghe I, Creancier L, Vispe S, Annereau JP, Barret JM, et al. (2008) Physalin B, a novel inhibitor of the ubiquitin-proteasome pathway, triggers NOXA-associated apoptosis. Biochem Pharmacol 76: 453-462.
57. Takahashi M, Iwasaki S, Kobayashi H, Okuda S, Murai T, et al. (1987) Rhizoxin binding to tubulin at the maytansine-binding site. Biochim Biophys Acta 926: 215-223.
58. Nakashima T, Miura M, Hara M (2000) Tetrocarcin A inhibits mitochondrial functions of Bcl-2 and suppresses its anti-apoptotic activity. Cancer Res 60: 1229-1235.